How to Deliver mRNA to T Cells In Vivo: Challenges and Solutions

Adoptive cell therapies such as CAR-T have revolutionized cancer treatment. However, traditional approaches rely on ex vivo cell engineering, which involves complex manufacturing, high cost, and long turnaround times.

An emerging alternative is in vivo CAR-T generation, where therapeutic genes (e.g., CAR constructs) are delivered directly into T cells inside the body. Among different strategies, mRNA delivery using lipid nanoparticles (LNPs) has gained increasing attention due to its safety and flexibility.

But delivering mRNA specifically to T cells in vivo remains a major challenge.

Why Is Delivering mRNA to T Cells So Difficult?

T cells are among the most challenging targets for in vivo delivery. Several biological barriers must be overcome:

1. Lack of Natural Uptake

Unlike hepatocytes, T cells do not naturally internalize lipid nanoparticles efficiently, making passive delivery ineffective.

2. Circulation and Biodistribution Barriers

After systemic administration, most nanoparticles accumulate in the liver or spleen, rather than reaching circulating or tissue-resident T cells.

3. Cell-Specific Targeting

Achieving specific delivery to T cells without affecting other immune or non-immune cells is critical for safety and therapeutic efficacy.

4. mRNA Stability and Expression

Even if delivery occurs, ensuring that mRNA remains stable and is efficiently translated into protein inside T cells is another layer of complexity.

Current Approaches for In Vivo mRNA Delivery

Several strategies have been explored to enable mRNA delivery to immune cells:

1）Viral Vectors

Viral systems (e.g., lentivirus, AAV) have been widely used for gene delivery.

Pros: High transduction efficiency

Cons: Safety concerns, immunogenicity, and limited re-dosing

Figure 1：Lentiviral vector

2）Conventional Lipid Nanoparticles (LNPs)

LNPs are the most established non-viral delivery system, especially for liver-targeted delivery.

• Pros: Clinically validated platform (e.g., mRNA vaccines)
• Cons: Poor targeting to T cells due to liver tropism

Figure 2：Lipid Nanoparticles（LNPs）

3）Physical Methods (Electroporation, etc.)

These methods are mainly used ex vivo and are not suitable for systemic in vivo delivery.

Limitations of Existing Solutions

Despite significant progress, current approaches still face major limitations:

❌ Lack of efficient T cell targeting capability

❌ Off-target delivery to liver and other organs

❌ Limited control over cell specificity

❌ Challenges in scaling for in vivo therapeutic applications

These limitations highlight the need for targeted, non-viral delivery systems.

A Targeted Solution: tLNP for T Cell-Specific mRNA Delivery

To overcome these challenges, targeted lipid nanoparticles (tLNPs) have emerged as a promising strategy.

What Is tLNP?

tLNP refers to lipid nanoparticles engineered with targeting ligands (e.g., antibodies or peptides) that enable selective binding to specific cell types, such as T cells.

Key Advantages of tLNP-Based Delivery

• T Cell-Specific Targeting：By incorporating targeting moieties, tLNPs can selectively deliver mRNA to T cells, improving precision.
• Non-Viral Safety Profile：Unlike viral vectors, tLNP systems are: Non-integrating, Less immunogenic, Suitable for repeat dosing.
• Flexibility for mRNA Payloads

tLNP platforms can be adapted for:

1. CAR constructs
2. Gene editing components
3. Immunomodulatory proteins

Enabling In Vivo CAR-T Generation

With targeted delivery, it becomes possible to:

👉 Generate CAR-T cells directly inside the body

👉 Avoid complex ex vivo manufacturing

👉 Accelerate treatment timelines

Levostar’s Approach

At Levostar, we focus on developing custom mRNA and targeted LNP delivery solutions to support advanced therapeutic research, including:

Custom mRNA synthesis for CAR constructs

Targeted LNP formulation for immune cell delivery

Optimization for in vivo gene delivery applications

👉 Learn more about our technology:

• mRNA synthesis services
• Targeted LNP delivery platforms

Conclusion: The Future of In Vivo mRNA Delivery

Delivering mRNA to T cells in vivo is a complex but critical step toward next-generation cell therapies.

While traditional approaches face limitations, targeted LNP systems offer a promising path forward by combining:

1. Precision targeting
2. Non-viral safety
3. Scalable manufacturing

As research continues to advance, tLNP-enabled delivery may play a key role in unlocking the full potential of in vivo CAR-T therapies.

Looking for a Custom Solution?

If you are exploring mRNA delivery or targeted LNP systems for your research, feel free to contact our team or find a local distributor for support.